Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer‐blinded head‐to‐head trial
| العنوان: | Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer‐blinded head‐to‐head trial |
|---|---|
| المؤلفون: | S. Sabeti‐Sandor, M. Hoke, Thomas Perkmann, Adrian Tanew, B. Strassegger, G. Holzer, Sonja Radakovic, A. Rauscher |
| المصدر: | Journal of the European Academy of Dermatology and Venereology. 35:441-449 |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Hemodynamics, Dermatology, 030204 cardiovascular system & hematology, Carotid Intima-Media Thickness, Severity of Illness Index, Gastroenterology, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Fumarates, Randomized controlled trial, Risk Factors, Psoriasis Area and Severity Index, law, Psoriasis, Internal medicine, Severity of illness, Adalimumab, medicine, Humans, Prospective Studies, Prospective cohort study, business.industry, medicine.disease, Treatment Outcome, Infectious Diseases, Blood pressure, Cardiovascular Diseases, Heart Disease Risk Factors, Dermatologic Agents, business, medicine.drug |
| الوصف: | Background The effect of adalimumab and fumaric acid esters (FAE) on the cardiovascular risk associated with psoriasis has only been investigated scarcely in randomized controlled studies. Objective The aim of this prospective, randomized controlled head-to-head trial was to compare the influence of adalimumab and FAE on cardiovascular disease markers in psoriasis patients. Methods Sixty-five patients with moderate to severe plaque psoriasis were randomly assigned to adalimumab or FAE treatment for 6 months. Cardiovascular haemodynamic parameters [flow-mediated dilation (FMD), nitro-glycerine mediated dilation (NMD) and carotid intima-media thickness (CIMT), blood pressure] were assessed at baseline (v0) and after 6 months (v6). Cutaneous disease severity, inflammatory and lipid cardiovascular risk markers were analysed at baseline(v0), after 3 (v3) and 6 months (v6). Results After 6 months of treatment FMD in the adalimumab group increased significantly [v0 5.9% (6.4% SD), v6 8.0% (4.8% SD), P = 0.048) but not in the FAE group. (v0 7.0% (4.1% SD), v6 8.4% (6.1% SD), P = 0.753]. This was paralleled by a significant decrease of high sensitive C-reactive protein (hsCRP) in the adalimumab group in comparison to the FAE group (v0: 0.39 mg/dL (0.38 SD), v6: 0.39 mg/dL (0.48 SD), P = 0.043). No significant changes were observed in any other haemodynamic parameters. FAE, however, additionally decreased total cholesterol (P = 0.046) and apolipoprotein B (P = 0.041) levels compared to adalimumab. Mean Psoriasis Area and Severity Index (psoriasis area severity score) reduction was greater but not significant (P = 0.116) under adalimumab treatment compared to FAE treatment [-71.1% (29.9 SD) vs. -54.6% (45.7%)]. Conclusion In our study, both treatments were documented to exert effects on the cardiovascular system. While adalimumab showed anti-inflammatory effects and improved FMD, FAE interacted favourably with the cholesterol metabolism. |
| تدمد: | 1468-3083 0926-9959 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::259ae92d408020cfb6003460c2913506Test https://doi.org/10.1111/jdv.16635Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....259ae92d408020cfb6003460c2913506 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14683083 09269959 |
|---|